Celcuity (NASDAQ: CELC) is one of 23 public companies in the “Medical laboratories” industry, but how does it contrast to its rivals? We will compare Celcuity to related businesses based on the strength of its risk, valuation, profitability, earnings, analyst recommendations, dividends and institutional ownership.
This is a breakdown of current ratings for Celcuity and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings & Valuation
This table compares Celcuity and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Celcuity Competitors||$1.13 billion||$90.54 million||392.67|
Celcuity’s rivals have higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
15.2% of Celcuity shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 43.5% of Celcuity shares are owned by company insiders. Comparatively, 16.7% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Celcuity and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Celcuity has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Celcuity’s rivals have a beta of 1.33, suggesting that their average share price is 33% more volatile than the S&P 500.
Celcuity beats its rivals on 7 of the 12 factors compared.
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.